REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Seven-membered Consisting Of One Nitrogen And Six Carbons Hetero Ring Is Seven-membered Consisting Of One Nitrogen And Six CarbonsHetero Ring Is Seven-membered Consisting Of One Nitrogen And Six Carbons patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027136 - Formulations of anthraquinone derivatives A stable, sterile aqueous solution of a compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R′R″ of at least 2 carbon atoms and R′ and R″ are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4 ... 02/16/06 - 20060035884 - N-cyclic sulfonamido inhibitors of gamma secretase Compounds of particular interest are defined by Formula I, wherein R4, R5, R6, R7, and R8, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula I. ... 01/26/06 - 20060019944 - Cyclopentylamine and cyclohexylamine derivatives as nk-1/ssri antagonists are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors. ... 01/26/06 - 20060019943 - Homopiperidine derivatives as nk-1 antagonists useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors. ... 12/29/05 - 20050288271 - Arylsulfonamides and uses related thereto Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: ... 11/24/05 - 20050261276 - Novel sulphones for inhibition of gamma secretase which are inhibitors of γ-secretase and hence useful in the treatment or prevention of Alzheimer's disease. ... 09/01/05 - 20050192269 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such ... 07/21/05 - 20050159405 - Substituted 10-aryl-11h-benzo[b]fluourenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors wherein: Re and ′Re are OH, optionally independently etherified or esterified; Z is —CH2CH2— or —C(R4,R5)—, wherein R4 and R5 are independently H, (1C-2C)alkyl or form together a spiro(3C-5C)cycloalkyl; R1 is H, halogen, CF3 , or (1C-4C)alkyl; R2 and R3 are independently H, halogen, —CF3, —OCF3, (1C-8C)alkyl, hydroxy, (1C-8C)alkyloxy, aryloxy, ... ### FreshPatents.com Support |